Loading...
•
Dec 31, 2020
Viking Therapeutics Q4 2020 Earnings Report
Announced financial results for the fourth quarter and year ended December 31, 2020, and provided a corporate update.
Key Takeaways
Viking Therapeutics reported a net loss of $10.9 million, or $0.15 per share, for the three months ended December 31, 2020. The company's cash, cash equivalents and short-term investments totaled $248.4 million.
Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Continues to Enroll
Phase 1 Trial Evaluating VK0214 Ongoing; Expect to Initiate Proof-of-Concept Trial in X-ALD Patients Mid-2021
Balance Sheet Remains Strong; Year-End Cash Approximately $250 Million
Marianne Mancini appointed to the position of COO and Greg Zante to CFO.